HighGravityDataCurrent guidance
1 items
ResMed
Guidance from ResMed’s last 8 earnings releases. Every value links to its sentence in the filing. See something wrong? Tell us.
Releases tracked
8
Latest release
Aug 6, 2026
Data checked
Aug 6, 2026
What changed in the Aug 6, 2026 release
Each item compared with the same item in the previous release (Apr 30, 2026). Values in quotation marks are the company’s words.
New — first stated in this releaseRaised / Lowered / Narrowed / Widened — changed from the prior releaseRevised — wording changed, direction not determinableChanged — value changed; the comparison couldn’t be parsed to a directionReiterated — restated unchangedNot restated — stated before, absent nowRaised and lowered describe the number, not whether the change is favorable.
No open guidance was changed or reiterated in this release.
Show 1 item not restated in this release
| Change | Metric | Period | Previous | Now | Source |
|---|---|---|---|---|---|
| Not restated | Ambition - people helped | for FY2030 | “more than 500 million people” | — | Filing ↗ |
Current guidance
Guidance for periods that have not yet ended, at its most recent value, grouped by horizon.
Next year and medium term
| Metric | Current value | Period | Measure | First stated | Times stated | Source |
|---|---|---|---|---|---|---|
| Ambition - people helped | “more than 500 million people” | for FY2030 | Company-defined | Oct 24, 2024 | 1 | Filing ↗ |
| Capital to be returned to shareholders through share repurchases and dividends | “more than $1.85 billion” | for FY2027 | Declared action | Aug 6, 2026 | 1 | Filing ↗ |
| Quarterly dividend | “$0.66 per quarter” | for FY2027 | Declared action | Aug 6, 2026 | 1 | Filing ↗ |
No period stated
| Metric | Current value | Period | Measure | First stated | Times stated | Source |
|---|---|---|---|---|---|---|
| Quarterly cash dividend | “$0.66 per share” | — | Declared action | Aug 6, 2026 | 1 | Filing ↗ |
How one item moved
Quarterly cash dividend, for FY2025 — every statement across the year, each linked to its filing.
How your Medical devices & equipment sector group guides
12 companies in Medical devices & equipment. What they guide on, and who reported this season.
Most-guided metric families
This season’s releases
| Medtronic | Sep 1, 2026 | 3 changes |
| Becton Dickinson | Aug 6, 2026 | 4 changes |
| ResMed | Aug 6, 2026 | 0 changes |
| Insulet | Aug 5, 2026 | 25 changes |
| Zimmer Biomet | Aug 5, 2026 | 3 changes |
| DexCom | Jul 30, 2026 | 3 changes |
| Stryker | Jul 30, 2026 | 2 changes |
| Boston Scientific | Jul 29, 2026 | 5 changes |
Get this for your own peer set — Peer Guidance Briefing, $3,000.
Full history
Every metric, every release, eight quarters — the complete record as one table.
| Metric | FY2030 | FY2027 | FY2026 | FY2025 | FY2024 | No period |
|---|---|---|---|---|---|---|
| Ambition - people helped | 1 statement | — | — | — | — | — |
| Capital to be returned to shareholders through share repurchases and dividends | — | 1 statement | — | — | — | — |
| Quarterly cash dividend | — | — | 2 statements | 4 statements | 1 statement | 1 statement |
| Quarterly dividend | — | 1 statement | — | — | — | — |
The full record for ResMed and its Medical devices & equipment peers, delivered as a Peer Guidance Briefing — PDF and Excel, every value linked to its filing.
Filings
The 8 earnings releases this page is built from.
| Filed | Fiscal period | Accession | Guidance items | |
|---|---|---|---|---|
| Aug 6, 2026 | FY2026 Q4 | 0001193125-26-337962 | 3 | Open filing ↗ |
| Apr 30, 2026 | FY2026 Q3 | 0001193125-26-197192 | 1 | Open filing ↗ |
| Jan 29, 2026 | FY2026 Q2 | 0001193125-26-029326 | 1 | Open filing ↗ |
| Oct 30, 2025 | FY2026 Q1 | 0001193125-25-258519 | 1 | Open filing ↗ |
| Jul 31, 2025 | FY2025 Q4 | 0001193125-25-170512 | 1 | Open filing ↗ |
| Apr 23, 2025 | FY2025 Q3 | 0001193125-25-091357 | 1 | Open filing ↗ |
| Jan 30, 2025 | FY2025 Q2 | 0001193125-25-017218 | 1 | Open filing ↗ |
| Oct 24, 2024 | FY2025 Q1 | 0001193125-24-242806 | 2 | Open filing ↗ |
Values in quotation marks are the company’s words; the classification and filing links are HighGravityData’s. HighGravityData does not score or rank companies or give investment advice.
Report an error